|
|
|
06.02.26 - 14:03
|
Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology (PR Newswire)
|
|
|
CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology.......
|
|
|
06.02.26 - 10:06
|
Fosun Pharma′s US$1.55 billion Eisai deal signals shift to long-term partnerships (SCMP)
|
|
|
A unit of Fosun Pharma has struck a US$1.55 billion deal to license its home-grown cancer drug to Japan's Eisai, adding to a wave of out-licensing agreements that are channelling billions of dollars into Chinese novel drug development.
The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners, shifting from simple one-off licensing fees, where a company is paid for granting rights to its drug, to long-term collaborations.
Under......
|
|
|
06.02.26 - 09:33
|
HUTCHMED to Announce 2025 Final Results (GlobeNewswire EN)
|
|
|
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT)....
|
|
|
|
|
06.02.26 - 00:33
|
Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 (GlobeNewswire EN)
|
|
|
ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton's tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application clearance from the China Center for Drug Evaluation (CDE) and is poised to enter a clinical study in patients with relapsed/refractory hematologic malignancies. This IND clearance from the China CDE, which came shortly after the IND was cleared by the U.S. Food and Drug Administration (FDA), ushers in a new phase in the multicenter clinical development of APG-3288 and highlights Ascentage Pharma's robust global development capabilities in the field of targeted protein degradation....
|
|
|
|
|
05.02.26 - 13:33
|
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York on Thursday, February 12, 2026 at 11:30 a.m. ET....
|
|
|
|
|
05.02.26 - 12:36
|
Everest Medicines and Micot partner on MT1013 commercialisation (PBR)
|
|
|
Under this agreement, Everest Medicines will make potential regulatory and commercial milestone payments of up to 1.04bn yuan ($149m) and an upfront payment of 200m yuan. Furthermore, Micot
The post Everest Medicines and Micot partner on MT1013 commercialisation appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
|
|
05.02.26 - 05:45
|
Research: Citi Re-rates REMEGEN at Buy/ High Risk w/ TP $105 (AAStocks)
|
|
|
Citi Research issued a research report renewing rating at Buy/High Risk on REMEGEN (09995.HK) after a period of Rating Suspended, with a target price of $105, as the Group's collaboration with AbbVie on the PD-1/VEGF candidate RC148, which further expanded the global potential of its pipeline candidates.The broker believed t......
|
|
|
04.02.26 - 18:42
|
Börsenradio Schlussbericht, Mi., 04.02.2026: Infineon oben, Novo unten -20%, Eli Lilly +9 %, OMV CFO-Interview (BRN)
|
|
|
Der DAX schließt bei 24.603 Punkten mit -0,7%. Nach gutem Start kippte die Stimmung, weil Schwergewichte wie SAP und Siemens schwächer waren und Tech auch in den USA nicht überzeugte. Bei den Einzelwerten springt Infineon nach Quartalszahlen und KI-Fantasie an die DAX-Spitze. Die Deutsche Telekom eröffnet in München ein KI-Rechenzentrum mit Nvidia-Technik und SAP-Software, erste Nutzer sind unter anderem Agile Robots und Quantum Systems. Henkel kauft Stahl Parent für 2,1 Mrd. Euro. Pharma liefert den Tagesknall: Novo Nordisk bricht -20% ein, der Ausblick für 2026 liegt bei -5% bis -13% bei Umsatz und Gewinn, nach +10% im Vorjahr. Eli Lilly legt dagegen +9% zu. In Deutschland überholt BYD Tesla: 2.629 Neuzulassungen im Januar, nach 235 im Vorjahr, Tesla kommt auf 1.301. Rohstoffe: Gold 4.923,54 USD/oz -0,47%, Silber 86,174 USD/oz +1,14%. Heute Abend warten die Märkte auf die Google-Zahlen. Zum Schluss eine Börsenweisheit: "Zeit ist Ihr Freund, Impuls Ihr Feind." John C. Bogle....
|
|
|
04.02.26 - 08:45
|
Research: M Stanley's Focus List for H Shares (Table) (AAStocks)
|
|
|
Morgan Stanley released a China market strategy report, listing Hong Kong and Chinese stocks in a focus list, removing YANGTZE POWER (600900.SH) while adding CHALCO (601600.SH):Stocks | Potential Upside from TPsAlibaba (BABA.US) | 3.3%CHALCO (601600.SH) | -1.9%CATL (300750.SZ) | 43.3%DUALITYBIO-B (09606.HK) | 46.4%ESPRESSIF (688......
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
